Sera Prognostics develops blood-based biomarker tests focused on maternal and neonatal health. Its first commercial product, the PreTRM® Test, is a clinically validated, commercially available blood-based biomarker test to accurately predict the risk of preterm birth. The company is led by Chairman and CEO Gregory C. Critchfield, M.D., M.S. Sera is building a pipeline of additional blood-based biomarker tests to predict other major pregnancy-related conditions beyond preterm birth. With the new financing the company plans to commercialize PreTRM® more broadly and accelerate development of its pipeline. It also intends to develop testing capacity to serve over 3 million annual U.S. pregnancies that are candidates for the PreTRM® Test. Sera Prognostics develops diagnostics to improve prenatal care by predicting individualized risk of preterm birth and other pregnancy complications. Its core product, the PreTRM test, is the only clinically-validated, commercially available biomarker blood test that assesses a woman’s individualized risk of premature delivery as early as 19 weeks' gestation. PreTRM measures proteins in the blood that are highly predictive of spontaneous preterm birth and is intended to enable earlier, more proactive clinical decisions designed to prolong gestation, improve neonatal health, and lower healthcare costs. The company plans to increase commercialization of PreTRM and to measure real-world clinical improvements and economic savings in collaboration with top health plans and providers. Sera is presented as a leading authority in biomarker preterm birth risk prediction, citing a key scientific publication in Obstetrics & Gynecology. Sera Prognostics is located in Salt Lake City, Utah. Sera Prognostics, based in Salt Lake City, Utah, develops women's health diagnostics aimed at improving outcomes for pregnant women and newborns. Its lead product, the PreTRM test, uses a routine second‑trimester blood sample to provide an early, individualized assessment of a woman's risk of preterm birth. The company planned to launch PreTRM in 2015; upon U.S. launch commercial testing will be performed at its CLIA laboratory with results returned to referring physicians. Sera received a $10M debt facility from Square 1 Bank and intends to use the proceeds to increase commercialization efforts. The PreTRM test is intended to enable physicians to better understand individualized preterm birth risk earlier in pregnancy and personalize care. Sera Prognostics develops tests to diagnose preterm birth and other pregnancy complications. The company is based in Salt Lake City, UT. Its lead product is a preterm birth diagnostic test that the company is preparing for commercial launch. The company plans to use newly raised funds for clinical trials and the commercial launch of that test. Sera raised $19.3M in a Series A financing to support these plans. As part of the financing, representatives from lead investors will join the company's board and the company appointed Gregory C. Critchfield, M.D. as CEO.

Total raised

$165M

Funding rounds

4

Latest round

Series E

Latest activity

May 2021